Asset profile
Sacubitril/valsartan · Entresto
Small molecule
Evidence outlook
Approved: Heart Failure
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Hypertension · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
114 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 114 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sacubitril / Valsartan (Entresto): this drug | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) | ||
| Ivabradine (Corlanor) | Approved | Small molecule | If (funny) channel | ||
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) |
…and 99 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
October 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (7)
January 2027 (1)
What to watch
April 2027 (3)
What to watch
What to watch
What to watch
December 2027 (3)
What to watch
What to watch
2028 (6)
May 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (2)
2029 (1)
June 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.